Geopolitical tension in the Middle East, steady Fed policy expectations, and a busy earnings calendar are giving investors a fresh reason to reassess large U.S. financial and health care stocks. When markets are pulled between military headlines and corporate results, many investors look for bigger, established companies that may handle shocks differently. This article walks through three stocks from a U.S. Large Cap Financials and Health Care Stocks screener that appear closely exposed to the latest news flow. It highlights how each could be positioned, positively or cautiously, in the current mix of risk and opportunity.

Alnylam Pharmaceuticals (ALNY)

Overview: Alnylam Pharmaceuticals is a biotechnology company that uses ribonucleic acid interference to develop and sell treatments for serious conditions such as hereditary amyloidosis, hypercholesterolemia, hemophilia, acute hepatic porphyria, and primary hyperoxaluria, while also advancing a large late stage and early stage pipeline across cardiovascular, metabolic, neurological, and rare diseases.

Operations: Alnylam generates about US$4.3b from discovering, developing, manufacturing, and commercializing RNAi therapeutics, with revenue concentrated in the United States at roughly US$2.6b, alongside meaningful contributions from Europe and the rest of the world.

Market Cap: US$35.7b

Alnylam Pharmaceuticals gives investors direct exposure to RNAi therapies that are already on the market, while a broad late stage pipeline in areas like hypertension, ATTR amyloidosis and neurology keeps the story driven by more than just a single drug. The company has recently become profitable, and analysts have discussed the potential for higher long term earnings if its Phase 2 and 3 programs progress as planned. At the same time, heavy use of external borrowing, high dependence on the TTR franchise and a premium P/E mean execution on new launches and AI driven R&D partnerships will be important from here. This is where the opportunity and the risk intersect.

Alnylam Pharmaceuticals now sits at the crossroads of new RNAi launches and a premium P/E, so the missing piece is whether the earnings story truly lines up with expectations in the analyst forecasts for Alnylam Pharmaceuticals

Insulet (PODD)

Overview: Insulet is a medical technology company that makes tubeless insulin delivery systems, with its Omnipod products helping people with insulin dependent diabetes manage their glucose through wearable pods that work with continuous glucose monitors and app based controls. It also supplies drug delivery pods for use in Amgen's Neulasta Onpro kit after chemotherapy.

Operations: Insulet generates about US$2.9b in revenue from drug delivery systems, with roughly US$2.1b coming from the United States and around US$844.9m from international markets.

Market Cap: US$11.4b

Insulet gives investors exposure to a growing diabetes technology platform, where recurring pod use, broad pharmacy channel access and expanding international reach tie into the screener’s focus on large, established health care stocks. The company is pushing deeper into the large type 2 diabetes segment and advancing fully closed loop systems. Analysts expect earnings and revenue to rise faster than the wider U.S. market. At the same time, Insulet is heavily reliant on the Omnipod franchise, currently dealing with several Class I recalls, a securities class action, and funds growth with higher risk external borrowing, all of which introduce execution and legal risk. How those strengths and fault lines balance out is what matters next for Insulet.

Insulet’s expanding diabetes platform and heavier legal and recall overhangs make the story feel unfinished, and the real tension sits in how the growth narrative lines up with the analyst forecasts for Insulet

Neurocrine Biosciences (NBIX)

Overview: Neurocrine Biosciences is a biopharmaceutical company that develops and sells treatments for neurological, psychiatric, endocrine, and immunological disorders, including INGREZZA for tardive dyskinesia and Huntington’s chorea, women’s health therapies such as Orilissa and Oriahnn, and CRENESSITY and related products for congenital adrenal hyperplasia.

Operations: Neurocrine Biosciences generates about US$3.1b in revenue from researching, developing, commercializing, and selling pharmaceuticals, with virtually all of this coming from the United States.

Market Cap: US$17.2b

Neurocrine Biosciences stands out in this screener as a large cap neurology and endocrine specialist with strong earnings momentum, a growing INGREZZA and CRENESSITY franchise, and a late stage central nervous system pipeline that reaches into areas like major depressive disorder, schizophrenia, epilepsy, and obesity. The company’s improving net margin of 21.6%, rising analyst earnings estimates, and a share price that screens well below some estimated fair value models have attracted attention. Yet the stock still carries clear trade offs, including concentration in a few key products, pricing and reimbursement pressure around Medicare, and rising commercial spend. How those strengths and fault lines show up in the full narrative for Neurocrine Biosciences is what many investors are watching now.

Neurocrine Biosciences appears to be an earnings story that the market has not fully connected yet, with INGREZZA, CRENESSITY and new programs reshaping expectations in the analyst forecasts for Neurocrine Biosciences

The three stocks covered here are just a starting point, and the full screener surfaced 13 more large cap U.S. financial and health care companies with equally compelling stories inside the U.S. Large Cap Financials and Health Care Stocks screener. Use Simply Wall St to identify, filter, and analyze the specific catalysts and narratives that matter most to you, so you can focus on the highest conviction opportunities across this group.

Take Control of Your Investment Journey

If Alnylam Pharmaceuticals or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Searching For Fresh Opportunities Elsewhere?

Fresh stock ideas do not stay under the radar for long, and the next breakout list can get caught by fast momentum before the crowd sees it. Consider acting while conditions still look favorable for your strategy.

• Target resilient cash generators by scanning a curated 48 high quality undervalued stocks that focuses on strong balance sheets and cash flows while prices are still dropping or stalling before wider attention arrives.
• Zero in on companies with staying power through a hand picked 81 resilient stocks with low risk scores designed to highlight businesses that may hold up when volatility increases again.
• Explore structural spending themes by checking a focused 33 power grid technology and infrastructure stocks built around critical infrastructure players that may attract interest before the broader market takes notice.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.